DFS

1 clinical trials · Condition

Record	Firm	Date
A Multicenter Randomized Controlled Study of Interventional Treatment for Operable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer With Potential Recurrence as Minimal Residual Disease(MRD) Positive (NCT06524518)	Xuanwu Hospital, Beijing	2024-08-01

Every clearance here is in the API, with alerts when new ones post.